56S1 Stock Chart & Stats
€167.50
€7.00(4.36%)
At close: 4:00 PM EDT
€167.50
€7.00(4.36%)
Day’s Range― - ―
52-Week Range€148.10 - €223.50
Previous CloseN/A
Volume28.00
Average Volume (3M)46.00
Market Cap
€16.56B
Enterprise Value€19.88K
Total Cash (Recent Filing)€203.90M
Total Debt (Recent Filing)€2.40B
Price to Earnings (P/E)55.2
Beta1.10
Next Earnings
Oct 22, 2026EPS Estimate
1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.02
Shares Outstanding97,330,410
10 Day Avg. Volume69
30 Day Avg. Volume46
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€230.00Price Target Upside37.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)5.02
Revenue Forecast (FY)€3.14B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueSartorius Stedim’s business model includes high-frequency consumables (single-use assemblies, filtration consumables) that create durable, repeatable revenue and strong customer stickiness. Consumable pull-through from installed capital equipment supports predictable demand and long-term revenue visibility.
Sharp Revenue Rebound And Improved LeverageA substantial TTM revenue rebound indicates resurgent end-market demand and better utilization of capacity. Combined with materially improved debt-to-equity, the company has strengthened its balance sheet, improving financial flexibility to invest in growth and absorb cyclical swings over the medium term.
Solid Operating Cash Flow BaseRobust operating cash flow provides a foundation for funding capital needs and R&D without overreliance on external financing. Improved free cash flow, even if still recovering, reflects better conversion of earnings and supports ongoing reinvestment into consumables, service capability, and selective capital projects.
Bears Say
Profitability Below Prior PeaksMargins remain materially below historical highs, suggesting persistent cost, mix, or pricing pressures. Sustained margin compression reduces return on invested capital, limits cash available for strategic initiatives, and means the company must rely on volume growth to restore profitability over several quarters.
Weak Free-cash-flow ConversionLow conversion of net income into free cash flow points to working-capital drag or elevated capex/other cash demands. This reduces the firm’s ability to rapidly deleverage, pay dividends, or fund bolt-on investments, making long-term cash returns more dependent on margin recovery and sustained revenue growth.
Sizable Absolute Debt And Modest ReturnsAlthough leverage ratios improved, the large absolute debt burden maintains fixed obligations and interest sensitivity. Combined with muted ROE, the capital structure constrains strategic optionality and heightens the need for consistent cash generation to rebuild shareholder returns and further reduce leverage.
Sartorius Stedim Biotech News
56S1 FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest stock price was €148.10 and its highest was €223.50 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is €16.56B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Oct 22, 2026 which is in 82 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Jul 23, 2026. The company reported €1.25 earnings per share for the quarter, missing the consensus estimate of €1.263 by -€0.013.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech does not currently pay dividends.
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.2.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of €1.25 in its last earnings report, missing expectations of €1.263. Following the earnings report the stock price went down -0.987%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in DE:56S1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.
56S1 Stock 12 Month Forecast
Average Price Target
€230.00
▲(37.31% Upside)